Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325326 | 1.00 | KCNH2 (0.63) | KCNH2 | |
| SCHEMBL2327153 | 1.00 | KCNH2 (0.63) | KCNH2 | |
| SCHEMBL2535481 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2535004 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2539418 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2535936 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2545079 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2535007 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2535933 | 0.91 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2539029 | 0.91 | KCNH2 (0.57) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193179-B2 | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-06-05 | — | — | US | claimed |
| EP-2167494-B1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-15 | — | — | US | claimed |
| US-8193179-B2 | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2167494-B1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179135-A1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ELANE, AAAS, DNPEP | KCNH2 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.